Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
Yehong Kuang, Yuzhen Li, Chengzhi Lv, Min Li, Zhenying Zhang, Yi Chen, Wendong Chen, Xingzhi Wang, Lina Ba, Yichen Zhong, Steven Feldman
INTRODUCTION: The treatment options for moderate to severe psoriasis (msPsO) in China have been greatly increased with the approvals of biologics. However, the unmet needs and treatment preferences of systemic treatments for msPsO in China remain unclarified. METHODS: Fifty dermatologists and 300 patients with msPsO (41% with severe psoriasis) were surveyed for effectiveness, safety, treatment convenience, and treatment preferences (using a choice-based conjoint questionnaire)...
May 11, 2024: Dermatology and Therapy
#2
JOURNAL ARTICLE
Impact of disease, musculoskeletal symptoms and disease control in the CorEvitas Psoriasis Registry.
Carly Grant, Lourdes M Perez-Chada, Ryan W Harrison, Robert R McLean, Blessing Dube, Margaux M Crabtree, Alice B Gottlieb, Joseph F Merola
BACKGROUND: Early identification, diagnosis and symptom control of psoriatic arthritis (PsA) in patients with psoriasis remain unmet medical needs. OBJECTIVES: To compare the impact of disease and other characteristics between patients with psoriasis who screened positive for PsA using the Psoriasis Epidemiology Screening Tool (PEST) (screen-positive group) and patients who (i) have PsA (PsA group) or (ii) screened negative for PsA (screen-negative group). Also, to determine the proportion of patients at a patient-acceptable symptom state (PASS) in the screen-positive and PsA groups...
March 5, 2024: Clinical and Experimental Dermatology
#3
JOURNAL ARTICLE
Sara Kamal Rizk, Azza Gaber Antar Farag, Samah El-Ghlban, Israa Salah Eldin Metwally
OBJECTIVES: This study aims to examine whether the genetic variants in the genes for Granzyme B (GZMB) and Interferon Induced with Helicase C domain 1 (IFIH1) were associated with psoriasis. BACKGROUND: Psoriasis, a papulosquamous skin disease, was initially thought of as a disorder primarily of epidermal keratinocytes but is now recognized as one of the most common immune-mediated disorders. It is caused by the interplay between multiple genetic and environmental risk factors...
May 11, 2024: Journal of Immunoassay & Immunochemistry
#4
REVIEW
Andreea Roxana Furtunescu, Simona Roxana Georgescu, Mircea Tampa, Clara Matei
Psoriasis is a highly prevalent dermatological disease associated with an increased systemic inflammatory response. In addition, joint involvement is also present in around 20% of patients. Therefore, treatment modalities used in this condition should be simultaneously effective at improving skin manifestations, reducing inflammation, and addressing psoriatic arthritis when present. Twenty years ago, the introduction of biologic treatments for psoriasis was a turning point in the management of this condition, offering an effective and reasonably safe option for patients whose disease could not be adequately controlled with conventional therapies...
April 25, 2024: International Journal of Molecular Sciences
#5
REVIEW
Siu Kan Law, Xiao Xiao Wu, Zhou Jiang, Christy Wing Sum Tong, Wesley Yeuk Lung Chow, Dawn Ching Tung Au
UNLABELLED: Chrysoeriol is an active ingredient derived from the Chinese medicinal herb (CMH) " Lonicerae japonicae flos " in the dried flower bud or bloomed flower of Lonicera japonica Thunberg. Dermatoses are the most common diseases in humans, including eczema, acne, psoriasis, moles, and fungal infections, which are temporary or permanent and may be painless or painful. Topical corticosteroids are widely used in Western medicine, but there are some side effects when it is continuously and regularly utilized in a large dosage...
April 25, 2024: Molecules: a Journal of Synthetic Chemistry and Natural Product Chemistry
#6
JOURNAL ARTICLE
Matteo Megna, Angelo Ruggiero, Fabrizio Martora, Ylenia Vallone, Gianluca Guerrasio, Luca Potestio
Guselkumab is the first approved human IgG1λ monoclonal antibody selectively targeting the p19 subunit of interleukin (IL)-23. Despite its effectiveness and safety, which have been widely reported by clinical trials and real-life experiences, data regarding its use on patients who previously failed anti-IL17 are limited or characterized by a reduced follow-up period. These data are essential to guide clinicians in biologic switching, considering that anti-IL23 and anti-IL17 partially share their therapeutic targets, as well as some patients who may have to interrupt treatment with anti-IL17 for loss of efficacy over time or the development of adverse events (AEs)...
May 3, 2024: Journal of Clinical Medicine
#7
JOURNAL ARTICLE
Matteo Megna, Anna Balato, Stefano Caccavale, Sara Cacciapuoti, Giulia Calabrese, Eugenia Veronica Di Brizzi, Luisa Di Costanzo, Raffaella Manzo, Vincenzo Marino, Rosa Valentina Puca, Francesca Romano, Oriele Sarno, Genoveffa Scotto di Luzio, Serena Lembo
Background: Guselkumab is the first approved human IgG1λ monoclonal antibody selectively targeting the p19 subunit of IL23. Its effectiveness and safety were widely reported by clinical trials. However, these results must be confirmed in real life since its safety deals with more complicated subjects with respect to trials. Currently, real-life data on the use of guselkumab following treatment failure with ustekinumab are limited, and existing studies usually show a small cohort and/or a reduced follow-up period...
April 26, 2024: Journal of Clinical Medicine
#8
JOURNAL ARTICLE
Emanuele Trovato, Martina Dragotto, Eugenio Capalbo, Alessandra Cartocci, Pietro Rubegni, Laura Calabrese
Background: The risk of developing non-melanoma skin cancers (NMSCs) in patients with psoriasis is highly debated, and, to date, there is no unambiguous consensus opinion. Psoriasis is known to be related to an increased likelihood of other comorbidities such as psoriatic arthritis, obesity, metabolic syndrome, depression, and cardiovascular disease. Regarding cancer risk, previous studies have reported a greater tendency for the development of cutaneous T-lymphomas and colon, breast, kidney, and lung cancers...
April 23, 2024: Journal of Clinical Medicine
#9
JOURNAL ARTICLE
Caroline Mann, Matthias Dreher, Jan-Niklas Rothschmidt, Petra Staubach
INTRODUCTION: Patients with chronic inflammatory skin diseases often suffer from sleep disturbances. However, objective data on sleep architecture, especially to evaluate potential overall influences under therapy, are lacking. PATIENTS AND METHODS: Pilot study on sleep quality changes including psoriasis and atopic dermatitis patients before and 2 weeks after intensive topical treatment. In addition to disease activity rating, patient-rated outcomes for itch severity and sleep quality and polygraphy was performed before and after topical therapy...
May 2024: Journal der Deutschen Dermatologischen Gesellschaft: JDDG
#10
REVIEW
Jeeyu Choi, Ikjoon Han, Joohong Min, Jisang Yun, Byung-Soo Kim, Kihyuk Shin, Kihun Kim, Yun Hak Kim
The association between psoriasis and alcohol consumption has been inconsistent across various studies. However, to the best of our knowledge, no dose-response meta-analysis has been performed to date. This study aims to investigate the association between alcohol consumption and psoriasis. The search was performed on July 27, 2021, using Embase and MEDLINE. The restricted cubic spline analysis was used to perform a dose-response analysis. We identified 3,904 studies, of which 48 studies with 1,702,847 individuals across 24 countries were included...
May 2024: Journal der Deutschen Dermatologischen Gesellschaft: JDDG
#11
JOURNAL ARTICLE
Lyanne Delgado-Coka, Michael Horowitz, Mariana Torrente-Goncalves, Lucia Roa-Peña, Cindy V Leiton, Mahmudul Hasan, Sruthi Babu, Danielle Fassler, Jaymie Oentoro, Ji-Dong K Bai, Emanuel F Petricoin, Lynn M Matrisian, Edik Matthew Blais, Natalia Marchenko, Felicia D Allard, Wei Jiang, Brent Larson, Andrew Hendifar, Chao Chen, Shahira Abousamra, Dimitris Samaras, Tahsin Kurc, Joel Saltz, Luisa F Escobar-Hoyos, Kenneth R Shroyer
BACKGROUND: The immune microenvironment impacts tumor growth, invasion, metastasis, and patient survival and may provide opportunities for therapeutic intervention in pancreatic ductal adenocarcinoma (PDAC). Although never studied as a potential modulator of the immune response in most cancers, Keratin 17 (K17), a biomarker of the most aggressive (basal) molecular subtype of PDAC, is intimately involved in the histogenesis of the immune response in psoriasis, basal cell carcinoma, and cervical squamous cell carcinoma...
May 10, 2024: Journal of Translational Medicine
#12
JOURNAL ARTICLE
Michal Shani, Irit Hermesh, Ilan Feldhamer, Orna Reges, Gil Lavie, Ronen Arbel, Yael Wolff Sagy
BACKGROUND: A large vaccination campaign was initiated worldwide in December 2020 in order to prevent infection with SARS-CoV-2 and severe Covid-19 disease. However, long-term adverse effects of vaccination remain unclear. Therefore, our objective was to examine the association between vaccination and the incidence of autoimmune diagnoses in the first year after vaccine uptake. METHODS: This retrospective cohort study based on Clalit Health Services (CHS) comprehensive database compared the rates of immune-mediated diagnoses among BNT162b2 vaccinated versus unvaccinated individuals...
May 9, 2024: Vaccine
#13
JOURNAL ARTICLE
Yuhang Zhou, Xiuping Yin, Chenyu Wang, Donglin Yu
Multiple studies have indicated a potential correlation between immune-mediated inflammatory diseases (IMIDs) and Frozen shoulder (FS). To explore the genetic causal relationship between IMIDs and FS using 2-sample Mendelian randomization (MR) analysis. Genome-wide association study (GWAS) summary data for FS were obtained from Green's study, while data for 10 IMIDs were sourced from the FinnGen Consortium. The MR analysis was performed using inverse variance weighting, MR Egger, and weighted median methods...
May 10, 2024: Medicine (Baltimore)
#14
JOURNAL ARTICLE
Robin Kikuchi, Paige Kingston, Audrey Hao, Kaviyon Sadrolashrafi, Rebecca K Yamamoto, Hannah Tolson, Sara N Bilimoria, Lily Guo, Danielle Yee, Maria T Ochoa, April W Armstrong
BACKGROUND: Shared decision-making (SDM) refers to a collaborative process in which clinicians assist patients in making medically informed, evidence-based decisions that align with their values and preferences. There is a paucity of literature on SDM in dermatology. OBJECTIVE: We aim to assess whether male and female psoriasis patients evaluate their clinicians' engagement in SDM differently across different age groups. METHODS: Cross-sectional study using data from the 2014-2017 and 2019 Medical Expenditure Panel Surveys (MEPS)...
2024: PloS One
#15
JOURNAL ARTICLE
Andreas Pinter, Ahmed M Soliman, Irina Pivneva, Roksana Ghanbariamin, Min Yang, Bang Truong, Luis Puig, Mark Lebwohl
INTRODUCTION: Real-world data on the efficacy of risankizumab (RZB) in clinical moderate-to-severe plaque psoriasis (PsO) are limited. The RAPID study assessed real-world clinical and patient-reported outcomes in RZB-treated PsO patients using data collected from dermatologists in Canada, the Czech Republic, Germany, Japan, and Poland. METHODS: This ongoing, retrospective chart review collected data from medical records of RZB-treated adults with moderate-to-severe PsO (09/2022-06/2023)...
May 10, 2024: Dermatology and Therapy
#16
JOURNAL ARTICLE
Sarah Alulis, Nicoletta Bernardini, Martina Burlando, Antonio Costanzo, Pier Cesare Francesa Morel, Paolo Gisondi, Francesco Loconsole, Matteo Megna, Giovanni Pellacani, Stefano Piaserico, Francesca Prignano, Ottavio Secchi, Nevena Skroza, Fareen Hassan
INTRODUCTION: There are several treatment options for plaque psoriasis (PsO), but uncertainty remains around the optimal sequencing of treatments. The aims of this study were to investigate how adopting a best-treatment-first treatment sequence impacts patient outcomes and healthcare systems and to quantify the cost of treatment failure to the healthcare system. METHODS: A 3-year state-transition treatment-sequencing model which identifies all possible treatment sequences in PsO was adapted to the Italian healthcare setting...
May 10, 2024: Dermatology and Therapy
#17
JOURNAL ARTICLE
Zahraa Ibrahim Abed, Mona Arianejad, Zahra Azizi
BACKGROUND: Psoriasis, a chronic inflammatory skin disease, is increasingly effectively managed with the targeted immunotherapy; however, long-term immunotherapy carries health risks, and loss of response. Therefore, we need to develop the alternative treatment strategies. Mesenchymal stem/stromal cell (M.S.C.) exosomes stand out for their remarkable immunomodulatory properties, gaining widespread recognition. This study investigated whether M.S.C. exosomes can reduce psoriasis-induced hyperplasia by inducing Transforming Growth Factor beta 2 (TGF-beta2) signaling...
May 10, 2024: Molecular Biology Reports
#18
JOURNAL ARTICLE
Giuseppe Argenziano, Francesco Cusano, Monica Corazza, Salvatore Amato, Paolo Amerio, Luigi Naldi, Cataldo Patruno, Paolo D Pigatto, Pietro Quaglino, Paolo Gisondi, Andrea Chiricozzi, Francesco Tonon, Luca Stingeni, Piergiacomo Calzavara-Pinton, Andreas Wollenberg, Maria Kinberger, Bernd W Arents, Nora Aszodi, Gabriela L Avila Valle, Sebastien Barbarot, Thomas Bieber, Helen A Brough, Piergiacomo Calzavara-Pinton, Stéphanie Christen-Zäch, Mette Deleuran, Martin Dittmann, Corinna Dressler, Antjie H Fink-Wagner, Nicole Fosse, Krisztián Gáspár, Louise A Gerbens, Uwe Gieler, Giampiero Girolomoni, Stamatios Gregoriou, Charlotte G Mortz, Alexander Nast, Uffe Nygaard, Magali Redding, Eva M Rehbinder, Johannes Ring, Mariateresa Rossi, Esther Serra-Baldrich, Dagmar Simon, Zsuzsanna Z Szalai, Jacek C Szepietowski, Antonio Torrelo, Thomas Werfel, Carsten Flohr
SIDeMaST (Società Italiana di Dermatologia Medica, Chirurgica, Estetica e delle Malattie Sessualmente Trasmesse) contributed to the development of the present guideline on the systemic treatment of chronic plaque psoriasis. With the permission of EuroGuiDerm, SIDeMaST adapted the guideline to the Italian healthcare context to supply a reliable and affordable tool to Italian physicians who take care of patients affected by atopic dermatitis. The evidence- and consensus-based guideline on atopic eczema was developed in accordance with the EuroGuiDerm Guideline and Consensus Statement Development Manual...
May 10, 2024: Italian journal of dermatology and venereology
#19
JOURNAL ARTICLE
Giuseppe Argenziano, Francesco Cusano, Monica Corazza, Salvatore Amato, Paolo Amerio, Luigi Naldi, Cataldo Patruno, Paolo D Pigatto, Pietro Quaglino, Paolo Gisondi, Andrea Chiricozzi, Francesco Tonon, Luca Stingeni, Piergiacomo Calzavara-Pinton, Andreas Wollenberg, Maria Kinberger, Bernd W Arents, Nora Aszodi, Gabriela L Avila Valle, Sebastien Barbarot, Thomas Bieber, Helen A Brough, Piergiacomo Calzavara-Pinton, Stéphanie Christen-Zäch, Mette Deleuran, Martin Dittmann, Corinna Dressler, Antjie H Fink-Wagner, Nicole Fosse, Krisztián Gáspár, Louise A Gerbens, Uwe Gieler, Giampiero Girolomoni, Stamatios Gregoriou, Charlotte G Mortz, Alexander Nast, Uffe Nygaard, Magali Redding, Eva M Rehbinder, Johannes Ring, Mariateresa Rossi, Esther Serra-Baldrich, Dagmar Simon, Zsuzsanna Z Szalai, Jacek C Szepietowski, Antonio Torrelo, Thomas Werfel, Carsten Flohr
SIDeMaST (Società Italiana di Dermatologia Medica, Chirurgica, Estetica e delle Malattie Sessualmente Trasmesse) contributed to the development of the present guideline on the systemic treatment of chronic plaque psoriasis. With the permission of EuroGuiDerm, SIDeMaST adapted the guideline to the Italian healthcare context to supply a reliable and affordable tool to Italian physicians who take care of patients affected by atopic dermatitis. The evidence- and consensus-based guideline on atopic eczema was developed in accordance with the EuroGuiDerm Guideline and Consensus Statement Development Manual...
May 10, 2024: Italian journal of dermatology and venereology
#20
REVIEW
Jacob Beer, Sarah Hermak, Omar Noor
No abstract text is available yet for this article.
May 2024: Journal of Clinical and Aesthetic Dermatology
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
